Prix
Questions fréquentes
Quelle est la capitalisation boursière de Calidi ?
Quel est le bénéfice par action (BPA) de Calidi ?
Quelles sont les évaluations des analystes et le prix cible de l'action Calidi ?
Quel est l'EBITDA de Calidi ?
Quel est le flux de trésorerie disponible de Calidi ?
Combien d'employés compte Calidi, et à quel secteur d'activité appartient-elle ?
Quel est le flottant des actions de Calidi ?
Finances
Capitalisation boursière
37,66 M $USBPA (TTM)
-5,611 $USFree Float
15,40 MEBITDA (TTM)
-27,17 M $USCash-flow disponible (TTM)
-19,54 M $USCotation
Notes des analystes
L'objectif de prix est de 20,00 $US et l'action est analysée par 1 analystes.
Acheter
1
Hold
0
Vendre
0
Informations
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Its clinical-stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses. Its preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach shall potentially treat, or even prevent, metastatic disease. Its product candidates include CLD-101 for Recurrent HGG; CLD-201 for Advanced Solid Tumors, and CLD-400 (RTNova) for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline product candidates, the Company's is also engaged in discovery research of CLD-301 (AAA) for multiple Indications.
41
Biotechnology & Drugs
Soins de santé
Identifiant
ISIN
Ticker primaire